BioCryst Q3 2026: Orladeyo Growth Decelerates but Profitability Holds; Guidance Maintained

What happened

BioCryst reported Q3 2026 total revenue of $180.3M with Orladeyo net revenue of $174.8M, representing roughly 10% year-over-year growth, a notable deceleration from 37% in Q3 2025. Non-GAAP operating profit reached $86.5M, and management narrowed full-year Orladeyo revenue guidance to $625–645M while raising total revenue guidance to $715–730M. The company also improved non-GAAP operating expense guidance to $415–425M, signaling better cost control than previously expected. FDA approval of ORLADEYO 150 mg oral pellets for patients aged 12 and older extends the pediatric formulation line but is unlikely to materially change near-term revenue. These results align with the deep value report's base case of stable Orladeyo cash flows and operating leverage, yet do not trigger a rating change, as growth remains above the 5% y/y thesis-stress threshold but below the pace required for an upgrade.

Implication

Investors should monitor whether Orladeyo growth stabilizes in the high single digits or continues to slide, as two consecutive quarters below 5% y/y would break the core cash-flow assumption. The maintained full-year guidance and improved opex outlook provide modest confidence in management's ability to deliver non-GAAP profitability despite higher interest costs from the Astria acquisition. However, the balance sheet remains stretched with ~$736M net debt and interest coverage under 1x, leaving little cushion against revenue disappointment or competitive shocks. The new oral pellet approval for ages 12+ may help pediatric adoption but is unlikely to shift the needle on near-term revenue. Until Orladeyo reaccelerates or navenibart Phase 3 data derisks the pipeline, the prudent stance remains WAIT with a bias toward accumulating only at prices below $5.50.

Thesis delta

The investment thesis is essentially unchanged; Q3 results confirm stable Orladeyo demand and improving operating leverage, but the sharp deceleration in growth from prior quarters is a yellow flag that must be watched closely. The improved non-GAAP opex guidance is a modest positive, yet it does not offset the risk of further growth slowdown. No thesis trigger has been hit: Orladeyo growth remains above the 5% downgrade threshold, and guidance has not been raised above $650M, so the WAIT rating stands.